- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Abiraterone
Abiraterone acetate is an oral androgen biosynthesis inhibitor indicated for the treatment of metastatic castration‑resistant prostate cancer (mCRPC) and metastatic high‑risk castration‑sensitive prostate cancer (mCSPC), in combination with prednisone or prednisolone. It works by selectively and irreversibly inhibiting cytochrome P450 17A1 (CYP17), an enzyme required for androgen production in the testes, adrenal glands, and tumour tissue. By blocking androgen synthesis, abiraterone reduces testosterone to castrate levels and slows the growth of prostate cancer cells that depend on androgens. It is not a chemotherapy drug and must be used together with a corticosteroid to manage mineralocorticoid‑related adverse effects.
Usual adult dose: The recommended dose of abiraterone is 1000 mg (four 250 mg tablets) taken orally once daily as a single dose, on an empty stomach (at least 1 hour before or 2 hours after a meal). The tablets must be swallowed whole with water; they should not be broken, crushed, or chewed. Abiraterone is always co‑administered with prednisone 5 mg twice daily (or prednisolone 5 mg once daily) for mCRPC, and with prednisone 5 mg once daily for mCSPC, to reduce the risk of mineralocorticoid excess. Treatment continues until disease progression or unacceptable toxicity. If a dose is missed, the patient should take the next dose at the usual time the following day; two doses must not be taken on the same day. Dose modifications may be required for hepatotoxicity or drug interactions; if a strong CYP3A4 inducer cannot be avoided, the abiraterone dose is increased to 1000 mg twice daily, but only on the advice of a specialist. No dose adjustment is required in renal impairment, but patients with moderate or severe hepatic impairment should not receive abiraterone unless the benefit clearly outweighs the risk, and liver function must be closely monitored.
Dosage form: Uncoated tablets: 250 mg (white to off‑white, oval‑shaped). Abiraterone is also available as 500 mg film‑coated tablets in some countries, but in Canada the 250 mg tablet is the standard strength, dispensed in bottles of 120 tablets.
Onset of action: Suppression of serum testosterone occurs within days of starting therapy; steady‑state plasma levels of abiraterone are achieved within approximately 2 weeks. Clinical benefit, measured by prostate‑specific antigen (PSA) response and radiographic progression‑free survival, is typically evaluated after 3 to 6 months of treatment.
Duration of action: Once‑daily dosing maintains continuous androgen synthesis inhibition. The elimination half‑life of abiraterone is approximately 12 hours; the effect on CYP17 is irreversible, so pharmacodynamic action extends well beyond the plasma half‑life. Treatment continues as long as clinical benefit is observed.
Alcohol recommendation: No direct interaction between abiraterone and alcohol has been established. However, alcohol is hepatically metabolized and may compound the risk of liver injury in patients receiving abiraterone, which is known to cause hepatotoxicity. Patients with liver impairment, heavy alcohol consumers, or those at risk of liver disease should limit or avoid alcohol and undergo regular liver function monitoring.
Most common side effects: The adverse effects are largely related to mineralocorticoid excess secondary to CYP17 inhibition and include hypertension, hypokalemia, fluid retention (peripheral edema), and atrial fibrillation. Other common events are fatigue, joint pain, hot flushes, diarrhea, urinary tract infection, and cough. Hepatotoxicity, manifesting as marked elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), can be serious and requires baseline and monthly liver function tests during the first few months of therapy; if Grade 2 or higher hepatotoxicity occurs, treatment must be interrupted or discontinued. Adrenal insufficiency can occur if prednisone is omitted or during stress; patients require corticosteroid stress dosing for surgery or infection. Osteoporosis and fractures are more frequent in patients on long‑term androgen deprivation. Abiraterone is not for use in women and is contraindicated during pregnancy; if used in females of child‑bearing potential, effective contraception is mandatory. This medication must be prescribed and supervised by an oncologist or a healthcare professional experienced in prostate cancer management.
Would you like to try Abiraterone without a prescription?
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
